<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04480710</url>
  </required_header>
  <id_info>
    <org_study_id>HEPA-CRV431-201</org_study_id>
    <nct_id>NCT04480710</nct_id>
  </id_info>
  <brief_title>A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects</brief_title>
  <acronym>AMBITION</acronym>
  <official_title>AMBITION: A Phase 2A, Multiple-Center, Single-Blind, Placebo-Controlled Study To Evaluate The Safety and Tolerability of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hepion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431
      in presumed NASH F2/F3 subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431
      in presumed NASH F2/F3 subjects. Study will evaluate the safety and tolerability of a once
      daily 75mg dose of CRV431 compared to placebo over 28 days of dosing. Pharmacokinetic
      parameters of CRV431 and its major metabolites and fraction unbound will also be evaluated.
      Non-invasive antifibrotic bio-markers will be collected and quantified from presumed NASH
      F2/F3 subjects dosed with 75mg CRV431 or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, multi-center, single-blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of safety and tolerability events of CRV431 versus placebo.</measure>
    <time_frame>28 days of dosing</time_frame>
    <description>Incidence of adverse events, serious adverse events, use of concomitant medications, and clinical laboratory abnormalities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of 75mg CRV431 in presumed NASH F2/F3 subjects.</measure>
    <time_frame>28 days of dosing</time_frame>
    <description>Measurement of maximum whole blood concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of 75mg CRV431 in presumed NASH F2/F3 subjects.</measure>
    <time_frame>28 days of dosing</time_frame>
    <description>Measurement of area under whole blood concentration-time curve from time 0 to various time points, last measurable concentration, infinity or 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of 75mg CRV431 in presumed NASH F2/F3 subjects.</measure>
    <time_frame>28 days of dosing</time_frame>
    <description>Measurement of time to reach maximum whole blood concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmin of 75mg CRV431 in presumed NASH F2/F3 subjects.</measure>
    <time_frame>28 days of dosing</time_frame>
    <description>Measurement of time to reach minimum whole blood concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of 75mg CRV431 in presumed NASH F2/F3 subjects.</measure>
    <time_frame>28 days of dosing</time_frame>
    <description>Measurement of elimination half-life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of 75mg CRV431 in presumed NASH F2/F3 subjects.</measure>
    <time_frame>28 days of dosing</time_frame>
    <description>Measurement of apparent total clearance of CRV431 from whole blood after oral administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F of 75mg CRV431 in presumed NASH F2/F3 subjects.</measure>
    <time_frame>28 days of dosing</time_frame>
    <description>Measurement of apparent volume of distribution during terminal phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent decrease from baseline to end of study of non-evasive antifibrotic markers.</measure>
    <time_frame>28 days of dosing</time_frame>
    <description>A change from baseline to end of study of non-evasive antifibrotic markers from subjects dosed with 75mg CRV431 versus placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <condition>Fibrosis, Liver</condition>
  <condition>NAFLD - Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>CRV431</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRV431, softgel capsule, 75mg, QD, 28 days, fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, softgel capsule, QD, 28 days, fasted conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRV431</intervention_name>
    <description>1 x 75mg softgel capsule</description>
    <arm_group_label>CRV431</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 x placebo softgel capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female between 18 and 75 years of age (inclusive).

          -  Capable of giving written informed consent and able to effectively communicate with
             the investigator and study personnel.

          -  Presumed F2/F3 NASH to include: AST &gt;20 IU/L, Pro-C3 &gt;15.5 ng/mL, enhanced liver
             fibrosis (ELF) score &gt;9.8, and FibroScan &gt;8.5 kPa values.

        Key Exclusion Criteria:

          -  Pregnant or breastfeeding or planning to become pregnant during the study period.

          -  Known allergy to CRV431, cyclosporine, or any of their inactive ingredients.

          -  Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies
             (HCVAb) or human immunodeficiency virus antibodies (HIVAb).

          -  Well documented causes of chronic liver disease according to standard diagnostic
             procedures to include any history or presence of decompensated cirrhosis.

          -  Subjects with a platelet count &lt;150,000/mL.

          -  Subjects with hemoglobin A1c(HbA1c) &gt;9.5%.

          -  Weight loss of more than 5% within 3 months prior to randomization.

          -  Subjects with a blood pressure to include a systolic pressure &gt;150 or a diastolic
             pressure &gt;90.

          -  At Screening, an estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 mL
             (calculated by the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] method)
             and/or a Kidney Disease Improving Global Outcomes (KDIGO) category of &gt;G2.

          -  Subjects with a history of organ transplantation. Corneal transplantation will be
             allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Canizares, R.Ph.</last_name>
    <role>Study Director</role>
    <affiliation>Hepion Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos Canizares, R.Ph.</last_name>
    <phone>973-972-4000</phone>
    <email>ccanizares@hepionpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Rodriguez</last_name>
    <phone>973-972-4000</phone>
    <email>arodriguez@hepionpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Conquest Clinical Research</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92866</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance Clinical Research</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>La Salud Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Covenant Research, LLC.</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quality Research Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FDI Clinical Research</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-fibrotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

